Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
CDK9 8 nM (Ki)
|
---|---|
ln Vitro |
CDDD11-8 (0-3 μM, 24 hours) inhibits the expression of c-MYC, MCL-1 and XIAP in MV4-11 and MOLM-13 cells [1]. CDDD11-8 dose-dependently inhibits proliferation (IC50 range: 281-734 nM), induces cell cycle arrest, and increases apoptosis in cell lines [2].
|
ln Vivo |
CDDD11-8 (0-125 mg/kg, orally, daily) can induce tumor regression [1].
|
Animal Protocol |
Animal/Disease Models: MV4-11 tumor-bearing mice[1]
Doses: 75 or 125 mg/kg Route of Administration: PO, daily for 5 or 28 days Experimental Results: Induced tumor regression. Potently inhibited the phosphorylation of RNAPII at Ser2 and Ser5, confirming the inhibition of CDK9 in vivo. Reduced phosphorylation of FLT3 at Tyr591 and STAT5 at Tyr 694. |
References |
Molecular Formula |
C24H26N6
|
---|---|
Molecular Weight |
398.503444194794
|
Exact Mass |
398.221
|
CAS # |
2241659-94-7
|
PubChem CID |
135301300
|
Appearance |
Off-white to light brown solid powder
|
LogP |
4.4
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
30
|
Complexity |
544
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
OVOYRPVIZNJKHS-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C24H26N6/c1-16-13-27-24(28-20-10-8-19(25)9-11-20)29-23(16)21-14-26-22-12-7-18(15-30(21)22)17-5-3-2-4-6-17/h2-7,12-15,19-20H,8-11,25H2,1H3,(H,27,28,29)
|
Chemical Name |
4-N-[5-methyl-4-(6-phenylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]cyclohexane-1,4-diamine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO :~100 mg/mL (~250.94 mM; with sonication)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5094 mL | 12.5471 mL | 25.0941 mL | |
5 mM | 0.5019 mL | 2.5094 mL | 5.0188 mL | |
10 mM | 0.2509 mL | 1.2547 mL | 2.5094 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.